DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis
ECCO'20 Vienna
2020
DOP08 Deep remission in paediatric Crohn’s disease is associated with increased abundance of dialister species and increased valerate
ECCO'20 Vienna
2020
DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy
ECCO'20 Vienna
2020
DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
ECCO'20 Vienna
2020
DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension
ECCO'20 Vienna
2020
DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
ECCO'20 Vienna
2020
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
ECCO'20 Vienna
2020
DOP15 Transmural healing with vedolizumab in patients with active Crohn’s disease
ECCO'20 Vienna
2020
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
ECCO'20 Vienna
2020
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
ECCO'20 Vienna
2020
DOP18 Impact of adherence to anti-tumour necrosis factor therapy on clinical outcomes in Crohn’s disease: A nationwide population-based study
ECCO'20 Vienna
2020
DOP19 Real-world healthcare resource utilisation among patients with inflammatory bowel disease administered vedolizumab for 6 months
ECCO'20 Vienna
2020
DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine
ECCO'20 Vienna
2020
DOP21 Time to first treatment with biologic agents for ulcerative colitis and Crohn’s disease across four Nordic countries: Results from the TRINordic study
ECCO'20 Vienna
2020
DOP22 Certification of integral care IBD Units: Evaluation of a certification program (CUE)
ECCO'20 Vienna
2020
DOP23 Endoscopic evaluation at 1 month after ileocolic resection for Crohn’s disease predicts postoperative recurrence and is safe
ECCO'20 Vienna
2020
DOP24 Patient-reported health-related quality-of-life outcomes with vedolizumab vs. adalimumab treatment of ulcerative colitis: Results of the VARSITY trial
ECCO'20 Vienna
2020